Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.46 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.46 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.46 |
| ▸ | AKT1 | P31749 | 2/20 | 0.44 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.43 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.43 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | GLA | P06280 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | CTSL | P07711 | 1/20 | 0.43 |
| ▸ | CTSB | P07858 | 1/20 | 0.43 |
| ▸ | CTSS | P25774 | 1/20 | 0.43 |
| ▸ | PTGES | O14684 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7473118 | 0.87 | LTB4R2 (0.49) | NR1H4HDAC3HDAC1HDAC2NCOR2 | |
| SCHEMBL5906827 | 0.86 | CHRM2 (0.50) | NR1H4HDAC3HDAC1HDAC2NCOR2 | |
| SCHEMBL4315970 | 0.86 | PTGES (0.54) | NR1H4HDAC3HDAC1HDAC2NCOR2 | |
| SCHEMBL19922245 | 0.86 | AKT1 (0.47) | NR1H4HDAC3HDAC1HDAC2NCOR2 | |
| SCHEMBL31434524 | 0.86 | AKT1 (0.44) | NR1H4HDAC3HDAC1HDAC2NCOR2 | |
| SCHEMBL6804016 | 0.85 | NR1H4 (0.49) | NR1H4HDAC3HDAC1HDAC2NCOR2 | |
| SCHEMBL3745549 | 0.84 | HDAC3 (0.60) | HDAC3HDAC1HDAC2NCOR2AKT1 | |
| SCHEMBL22042475 | 0.84 | TRPM8 (0.45) | NR1H4HDAC3HDAC1HDAC2NCOR2 | |
| SCHEMBL5906599 | 0.84 | AKT1 (0.42) | NR1H4HDAC3HDAC1HDAC2NCOR2 | |
| SCHEMBL28628157 | 0.83 | LTB4R2 (0.56) | NR1H4HDAC3HDAC1HDAC2NCOR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113164481-B | Cycloalkane-1, 3-diamine derivatives | 第一三共株式会社 | 2024-08-30 | — | — | CN | disclosed |
| US-20230074669-A1 | CYCLOALKANE-1,3-DIAMINE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2023-03-09 | — | — | US | disclosed |
| US-20230030720-A1 | CYCLOALKANE-1,3-DIAMINE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2023-02-02 | — | — | US | disclosed |
| US-11236106-B2 | Cycloalkane-1,3-diamine derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2022-02-01 | — | — | US | disclosed |
| EP-3892278-A1 | CYCLOALKANE-1,3-DIAMINE DERIVATIVE | Daiichi Sankyo Company, Limited (JP) | 2021-10-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11236106-B2 | Cycloalkane-1,3-diamine derivative | MLLT1, MEN1, MLLT3 | NR1H4 1076/4885HDAC3 485/4885HDAC1 483/4885 |
| US-20230030720-A1 | CYCLOALKANE-1,3-DIAMINE DERIVATIVE | MLLT1, MEN1, MLLT3 | NR1H4 1076/4885HDAC3 485/4885HDAC1 483/4885 |
| US-20230074669-A1 | CYCLOALKANE-1,3-DIAMINE DERIVATIVE | MLLT1, MEN1, MLLT3 | NR1H4 1076/4885HDAC3 485/4885HDAC1 483/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.